AU2021297458B2 - Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy - Google Patents
Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapyInfo
- Publication number
- AU2021297458B2 AU2021297458B2 AU2021297458A AU2021297458A AU2021297458B2 AU 2021297458 B2 AU2021297458 B2 AU 2021297458B2 AU 2021297458 A AU2021297458 A AU 2021297458A AU 2021297458 A AU2021297458 A AU 2021297458A AU 2021297458 B2 AU2021297458 B2 AU 2021297458B2
- Authority
- AU
- Australia
- Prior art keywords
- tcr
- cells
- cell
- eso
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K40/4269—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/47—Brain; Nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044150P | 2020-06-25 | 2020-06-25 | |
| US63/044,150 | 2020-06-25 | ||
| PCT/US2021/039262 WO2021263211A2 (en) | 2020-06-25 | 2021-06-25 | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2021297458A1 AU2021297458A1 (en) | 2023-02-02 |
| AU2021297458B2 true AU2021297458B2 (en) | 2026-06-18 |
Family
ID=79281973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2021297458A Active AU2021297458B2 (en) | 2020-06-25 | 2021-06-25 | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230250149A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4171587A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7781085B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN116322750A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021297458B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3188143A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021263211A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4519675A4 (en) * | 2022-05-03 | 2026-04-08 | 3T Biosciences Inc | T-LYMPHOCYTE TARGET DISCOVERY |
| WO2023228968A1 (ja) * | 2022-05-25 | 2023-11-30 | 国立大学法人東海国立大学機構 | ポリヌクレオチド |
| WO2024163292A1 (en) * | 2023-01-30 | 2024-08-08 | Board Of Regents, The University Of Texas System | T-cell receptors targeting her2 and methods of use thereof |
| WO2024263821A2 (en) * | 2023-06-20 | 2024-12-26 | The Methodist Hospital | Antigen-specific t cell receptors and chimeric antigen receptors, and methods of use in immune signaling modulation for cancer immunotherapy |
| AU2024312524A1 (en) * | 2023-06-20 | 2026-01-22 | Immunova Therapeutics Llc | Synthetic t cell receptors for enhancing memory (stem) t cells using new transmembranes and signaling domains |
| WO2025084880A1 (ko) * | 2023-10-20 | 2025-04-24 | 주식회사 이온셀 | Ct83 항원에 결합하는 car-t 세포 및 이의 용도 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193696A1 (en) * | 2015-06-01 | 2016-12-08 | Ucl Business Plc | Cell |
| WO2017120546A1 (en) * | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Conditionally active heterodimeric polypeptides and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2951202T (pt) * | 2013-01-29 | 2020-07-07 | Max Delbruck Centrum Fur Molekulare Medizin Mdc Berlin Buch | Moléculas de ligação de alta avidez que reconhecem mage-a1 |
| CA2912389C (en) * | 2013-06-10 | 2020-01-28 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Methods and compositions for reducing immunosupression by tumor cells |
| EP3104866A4 (en) * | 2014-02-14 | 2017-08-02 | Bellicum Pharmaceuticals, Inc. | Methods for activating t cells using an inducible chimeric polypeptide |
| RU2716716C2 (ru) | 2014-10-27 | 2020-03-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии |
| KR102546296B1 (ko) * | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| MA44907A (fr) * | 2015-09-11 | 2018-07-18 | Agenus Inc | Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation |
| AU2017232431A1 (en) * | 2016-03-15 | 2018-09-20 | Cancer Research Technology Limited | Chimeric antigen receptor |
| US20210079061A1 (en) | 2018-02-26 | 2021-03-18 | Fred Hutchinson Cancer Research Center | Compositions and methods for cellular immunotherapy |
| WO2019241688A1 (en) * | 2018-06-14 | 2019-12-19 | Bluebird Bio, Inc. | Cd79b chimeric antigen receptors |
| CN113454110B (zh) * | 2018-10-23 | 2024-07-02 | 里珍纳龙药品有限公司 | Ny-eso-1 t细胞受体和其使用方法 |
-
2021
- 2021-06-25 AU AU2021297458A patent/AU2021297458B2/en active Active
- 2021-06-25 JP JP2022579946A patent/JP7781085B2/ja active Active
- 2021-06-25 WO PCT/US2021/039262 patent/WO2021263211A2/en not_active Ceased
- 2021-06-25 US US18/002,969 patent/US20230250149A1/en active Pending
- 2021-06-25 CN CN202180056522.1A patent/CN116322750A/zh active Pending
- 2021-06-25 EP EP21827918.0A patent/EP4171587A4/en active Pending
- 2021-06-25 CA CA3188143A patent/CA3188143A1/en active Pending
-
2025
- 2025-08-18 JP JP2025136019A patent/JP2025166212A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016193696A1 (en) * | 2015-06-01 | 2016-12-08 | Ucl Business Plc | Cell |
| WO2017120546A1 (en) * | 2016-01-08 | 2017-07-13 | The Regents Of The University Of California | Conditionally active heterodimeric polypeptides and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3188143A1 (en) | 2021-12-30 |
| EP4171587A2 (en) | 2023-05-03 |
| WO2021263211A3 (en) | 2022-03-10 |
| JP2023532278A (ja) | 2023-07-27 |
| JP7781085B2 (ja) | 2025-12-05 |
| WO2021263211A9 (en) | 2022-02-03 |
| CN116322750A (zh) | 2023-06-23 |
| EP4171587A4 (en) | 2024-07-24 |
| JP2025166212A (ja) | 2025-11-05 |
| WO2021263211A2 (en) | 2021-12-30 |
| AU2021297458A1 (en) | 2023-02-02 |
| US20230250149A1 (en) | 2023-08-10 |